Drugs / OTP-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07266428 | Dec 2025 → Dec 2028 expected | cancer | Ottimo Pharma Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-07 | Ottimo Pharma Limited | Regulatory Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody ottimopharma.com ↗
Ottimo Pharma (“Ottimo”), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of patients living with cancer, today announces the US Food and Drug Administration clearance of the investigational new drug (IND) application for its lead candidate OTP-01. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-07 | Ottimo Pharma Limited | Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody ottimopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTP-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07266428 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT07266428 ↗ |